CYP 8.62% 26.5¢ cynata therapeutics limited

Ann: CYP Enters Letter of Intent for Strategic Alliance in Japan, page-24

  1. 634 Posts.
    Not sure what the problem is. As a reminder, ---- Cynata and Regience have identified a mutually beneficial business opportunity to enter a business partnership under which Regience would license, develop and commercialise Cynata’s proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) technology in certain territories, including Japan.

    It's a business partnership, not a charity. Regience is interested to license, develop and commercialise Cynatata's MSC technology, exactly what Ross MacDonald said companies would be interested to do. This is proof that this is indeed a viable strategy and companies would want to do exactly that. Yes, Regience is a small company but it doesn't take away the fact that this seems like a legitimate business model and there is no doubt that as the need for stem cells in pharmaceutical therapy increases, we will see even more companies queuing up to license CYP's unique technology. I think this is a hold and it would be a mistake to sell into any news in the long run.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
26.5¢
Change
-0.025(8.62%)
Mkt cap ! $47.60M
Open High Low Value Volume
28.5¢ 28.5¢ 26.5¢ $30.17K 112.9K

Buyers (Bids)

No. Vol. Price($)
2 28895 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
28.5¢ 500 1
View Market Depth
Last trade - 16.10pm 04/07/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.